Inventor · disambiguated record
Mark D. Okusa
Also filed as: OKUSA MARK · OKUSA MARK D
8 granted patents·3 pending applications·230 citations·filing 1999–2024
89Inventor score
Top patents by PatentIndex Score
11 records- 0192US10851145B2Methods for treating inflammation with fusion proteins comprising interleukin-2 and interleukin-33UNIV VIRGINIA PATENT FOUNDATION·Filed 2017·Granted Dec 1, 2020·5 cites·16 claims
- 0292US6531457B2Methods and compositions for treating inflammatory responseUniv Virginia Patent Found·Filed 2001·Granted Mar 11, 2003·63 cites·14 claims
- 0391US9840545B2Fusion protein comprising interleukin-2 and interleukin-33UNIV VIRGINIA PATENT FOUNDATION·Filed 2014·Granted Dec 12, 2017·8 cites·8 claims
- 0490US6232297B1Methods and compositions for treating inflammatory responseUNIV VIRGINIA·Filed 1999·Granted May 15, 2001·112 cites·48 claims
- 0586US7226913B2Pharmaceutical compositions having A2A adenosine receptor agonist activityUNIV VIRGINIA·Filed 2003·Granted Jun 5, 2007·23 cites·18 claims
- 0685US7396825B2Agonists of A2A adenosine receptors for treatment of diabetic nephropathyUNIV VIRGINIA·Filed 2005·Granted Jul 8, 2008·13 cites·58 claims
- 0783US2025074963A1Compositions and methods for treatment of autoimmune and inflammatory diseases and disordersUNIV VIRGINIA PATENT FOUNDATION·Filed 2024·Application pending·0 cites
- 0873US12060401B2Compositions and methods for treatment of autoimmune and inflammatory diseases and disordersUNIV VIRGINIA PATENT FOUNDATION·Filed 2020·Granted Aug 13, 2024·0 cites·17 claims
- 0966US7169818B2Lysophosphatidic acid receptor agonists and antagonistsUNIV VIRGINIA·Filed 2001·Granted Jan 30, 2007·6 cites·22 claims
- 1061US2007265440A1Methods and compositions for treating inflammatory responseUNIV VIRGINIA·Filed 2007·Application pending·0 cites
- 1139US2019083817A1Systems, methods, and computer readable media for ischemic injury protective ultrasoundUNIV VIRGINIA PATENT FOUNDATION·Filed 2017·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →